Janney Capital Maintains Neutral On Alexion Despite A Positive Outlook For 2Q14 Results
In a research note published today, Janney Capital analyst Kimberly Lee maintained a Neutral rating on Alexion Pharmaceuticals (ALXN) with a $162 price target, which suggests a slight downside to shares.
Lee noted, “We believe the company could come in ahead of our 2Q Soliris revenue of 507.9 million (consensus $509.3 million) and EPS of $0.76 (consensus $0.78) based on continued growth in PNH in the emerging markets. On the earnings call, we anticipate updates on Soliris growth trends, progress in new geographies for Soliris, commentary on the EU reimbursement environment and a pipeline update with emphasis on asfotase alfa”.
According to TipRanks.com, which measures analysts and bloggers success rate based on how their calls perform, analyst Kimberly Lee currently has a one-year average return of 12.0% and a 53% success rate. Lee is ranked #970 out of 3213 analysts.